Effect of CT1812 Treatment on Brain Synaptic Density
Status:
Active, not recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, double-blind, placebo-controlled, parallel group study
of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the
safety and tolerability of oral CT1812, administered for up 180 days for the Primary study
and another 180 days for the Double blind extension study.